RECURRENT PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Clinical trials for RECURRENT PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Vaccine-Immunotherapy combo takes aim at Hard-to-Treat ovarian cancer
Disease control OngoingThis phase 2 trial tests whether combining a vaccine that targets the p53 protein (p53MVA) with the immunotherapy drug pembrolizumab can shrink tumors in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to platinum-based ch…
Matched conditions: RECURRENT PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 women will receive one of s…
Matched conditions: RECURRENT PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New cocktail of drugs could offer hope for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether adding immunotherapy (atezolizumab) and/or a blood vessel blocker (bevacizumab) to standard chemo (pegylated liposomal doxorubicin) works better for ovarian cancer that has stopped responding to platinum drugs. About 444 women with recurrent ovarian, fall…
Matched conditions: RECURRENT PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC